title: Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the rat.
abstract: We have recently presented evidence that a macrophage scavenger receptor-mediated pathway is responsible for the hepatic uptake of unfractionated heparins and low-molecular-weight heparins (LMWHs) in the rat. The same receptor-mediated pathway was partially responsible for the removal of oxidized low-density lipoprotein. Unfractionated and fractionated LMWHs exert their anticoagulatory effects predominately by reversibly binding to the plasma glycoprotein antithrombin III. In this study LMWHs modified by endpoint attachment of tyramine were radiolabeled and their fractions with low or high affinity to AT-III studied in vivo in rats. The high-affinity fraction was predominately cleared from the circulation by a hepatic uptake mechanism. About 25% of the injected high-affinity tracer material was recovered, whereas only about 8% of the low-affinity material was found in the liver after 180 minutes. Blocking the scavenger receptor-mediated liver RES uptake mechanism by maleylated bovine serum albumin led to a considerable decline in liver uptake (9 versus 25%). The low-affinity material was rapidly eliminated into the urine after 180 minutes. About 45% of the low-affinity material was excreted versus 23% of the high-affinity material. Tight binding to AT-III prevented LMWH-tyramine from being rapidly cleared from the circulation via the kidneys into the urine; instead, the scavenger receptor-mediated hepatic uptake mechanism seemed to be more dominant in removing material with high affinity to AT-III from blood.
authors.affiliation: 1st Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Stehle
authors.forename: A
authors.initials: A
authors.lastname: Wunder
authors.forename: H
authors.initials: H
authors.lastname: Sinn
authors.forename: H H
authors.initials: HH
authors.lastname: Schrenk
authors.forename: J
authors.initials: J
authors.lastname: Harenberg
authors.forename: R
authors.initials: R
authors.lastname: Malsch
authors.forename: W
authors.initials: W
authors.lastname: Maier-Borst
authors.forename: D L
authors.initials: DL
authors.lastname: Heene
mesh_terms: D000818:Animals; D000990:Antithrombin III / Q000819:agonists*; D002417:Cattle; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000378:metabolism / Q000493:pharmacokinetics*; D006801:Humans; D008565:Membrane Proteins; D051381:Rats; D017208:Rats, Wistar; D011971:Receptors, Immunologic / Q000378:metabolism; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D051122:Scavenger Receptors, Class B; D014018:Tissue Distribution; D014439:Tyramine
chemical_list: D006495:Heparin, Low-Molecular-Weight; D008565:Membrane Proteins; D011971:Receptors, Immunologic; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; C454739:Scarb1 protein, mouse; D051122:Scavenger Receptors, Class B; D000990:Antithrombin III; D014439:Tyramine